Company intelligence
Fovus
The world's first AI-powered serverless HPC platform for bioinformatics, computational chemistry, simulations, and AI
About Fovus
š šØšÆš®š¬ š¢š¬ šš”š ššØš«š„š'š¬ š š¢š«š¬š šš-ššØš°šš«šš ššš«šÆšš«š„šš¬š¬ ššš šš„ššššØš«š¦, built for scientists and engineers accelerating drug discovery, engineering simulations, and AI research. GPU scarcity, long queues, manual benchmarking, and job failures slow the world's most valuable scientific workloads down and burn millions in cloud spend. Fovus removes these bottlenecks. The platform benchmarks every workload to choose the optimal instance, parallelizes across AWS regions to unlock capacity, and runs on Spot with memory checkpointing so interruptions don't kill long jobs. šš”š šØš®šššØš¦š: šØšÆšš« šššš± ššš¬ššš« šš¢š¦š-ššØ-š¢š§š¬š¢š š”š. šš% ššØ šš% š„šØš°šš« ššØš¦š©š®šš ššØš¬š. These results are published. In a benchmarking study on the AWS Partner Network blog, co-authored with AWS, Fovus delivered nf-core/rnaseq at $0.70 per sample and 30x whole genome sequencing with sarek at $6.15 per sample, running 3x faster. An AWS HPC and Software Competency Partner, Fovus powers compute for enterprise pharma, biotech, and research teams running Nextflow (RNA-seq, sarek WGS), AlphaFold, Boltz, and GROMACS.
Verified activity
Signals from Fovus
2 published signals
Presence & Recognition
Fovus participated in the Amazon Web Services (AWS) Startup Summit in San Francisco to share its platform and push deeper into enterprise.
Reported by Fovus
Presence & Recognition
Fovus is participating in the Boston AI Week event on October 2 to judge teams for the Drug Discovery Challenge at Amazon Web Services.
Reported by Fovus